III CONGRESO DEONTOLOGIA MEDICA

120-121 / 956

 Naud PS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18
AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4
years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147-62.
 Australia. Gardasil (quadrivalent human papillomavirus vaccine), update 2.
Update - adverse event monitoring. 13 may 2015.
 Scheller NM, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis
and other demyelinating diseases of the central nervous system. JAMA.
2015;313(1):54-61.
 MSSSI. Nota informativa de la AEMPS sobre Seguridad de la Vacuna frente al
Virus del Papiloma Humano Gardasil®. 16 de febrero de 2009.